Your browser is no longer supported. Please, upgrade your browser.
Settings
OLMA [NASD]
Olema Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own2.90% Shs Outstand39.41M Perf Week2.16%
Market Cap1.16B Forward P/E- EPS next Y-2.54 Insider Trans-9.79% Shs Float35.74M Perf Month1.16%
Income- PEG- EPS next Q-0.45 Inst Own94.70% Short Float5.77% Perf Quarter6.58%
Sales- P/S- EPS this Y-455.80% Inst Trans5.25% Short Ratio7.07 Perf Half Y-26.05%
Book/sh7.97 P/B3.50 EPS next Y-48.80% ROA- Target Price- Perf Year-
Cash/sh7.66 P/C3.64 EPS next 5Y- ROE- 52W Range19.41 - 60.27 Perf YTD-42.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.77% Beta-
Dividend %- Quick Ratio39.40 Sales past 5Y- Gross Margin- 52W Low43.53% ATR1.56
Employees36 Current Ratio39.40 Sales Q/Q- Oper. Margin- RSI (14)49.14 Volatility5.89% 4.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-847.10% Profit Margin- Rel Volume1.33 Prev Close26.56
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume291.93K Price27.86
Recom1.60 SMA20-4.03% SMA503.95% SMA200-18.16% Volume388,381 Change4.89%
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
Sep-09-21 07:30AM  
Aug-30-21 04:05PM  
Aug-18-21 10:46AM  
Aug-10-21 04:05PM  
Jul-28-21 04:05PM  
May-18-21 04:05PM  
May-11-21 04:05PM  
Apr-07-21 07:30AM  
Apr-06-21 07:30AM  
Mar-17-21 04:05PM  
Mar-10-21 04:45PM  
Feb-23-21 07:00AM  
Feb-19-21 04:59AM  
Dec-31-20 03:42PM  
Dec-17-20 07:00AM  
Dec-07-20 07:39AM  
Dec-03-20 05:18PM  
Nov-23-20 04:01PM  
Nov-20-20 01:33PM  
Nov-19-20 06:39PM  
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harmon CyrusCHIEF TECHNOLOGY OFFICERSep 20Sale26.3012,000315,6001,063,546Sep 21 06:19 PM
Horn KinneyCHIEF BUSINESS OFFICERSep 10Option Exercise2.065,25110,8387,041Sep 13 08:07 PM
Horn KinneyCHIEF BUSINESS OFFICERSep 10Sale29.385,251154,2741,790Sep 13 08:07 PM
Bohen SeanPRESIDENT AND CEOSep 08Option Exercise4.822,63112,69256,905Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 08Sale30.002,63178,93052,514Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 07Option Exercise4.824131,99254,687Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 07Sale30.0841312,42354,274Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 01Option Exercise4.828714,20255,145Sep 03 05:16 PM
Bohen SeanPRESIDENT AND CEOSep 01Sale30.0587126,17454,274Sep 03 05:16 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERAug 19Sale24.9712,000299,6401,075,546Aug 20 09:14 PM
Horn KinneyCHIEF BUSINESS OFFICERAug 10Option Exercise2.065,25110,8387,041Aug 11 06:05 PM
Horn KinneyCHIEF BUSINESS OFFICERAug 10Sale25.715,251134,9791,790Aug 11 06:05 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERJul 20Sale25.634,123105,6721,087,546Jul 21 05:29 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERJul 19Sale24.837,877195,5861,091,669Jul 21 05:29 PM
Horn KinneyCHIEF BUSINESS OFFICERJul 12Option Exercise2.065,25110,8387,041Jul 13 06:27 PM
Horn KinneyCHIEF BUSINESS OFFICERJul 12Sale26.515,251139,1911,790Jul 13 06:27 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERJun 18Sale24.8012,000297,6261,099,546Jun 21 07:05 PM
Horn KinneyCHIEF BUSINESS OFFICERJun 10Option Exercise2.065,25110,8387,041Jun 11 04:30 PM
Horn KinneyCHIEF BUSINESS OFFICERJun 10Sale29.725,251156,0711,790Jun 11 04:30 PM
Horn KinneyCHIEF BUSINESS OFFICERMay 18Option Exercise2.0657,763119,22359,553May 19 08:18 PM
Horn KinneyCHIEF BUSINESS OFFICERMay 18Sale24.1557,7631,394,7691,790May 19 08:18 PM
Cormorant Asset Management, LPFormer 10% OwnerNov 23Buy19.00425,0008,075,0003,270,544Nov 23 04:59 PM
Graham G. WalmsleyDirectorNov 23Buy19.001,160,00022,040,0001,160,000Nov 23 04:35 PM